{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:02:04Z","timestamp":1781888524064,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T00:00:00Z","timestamp":1525219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Actelion Parmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1577-0","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T12:42:37Z","timestamp":1525264957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts"],"prefix":"10.1186","volume":"20","author":[{"given":"Maurizio","family":"Cutolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ruaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Montagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Brizzolara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Stratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia Chiara","family":"Trombetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Scabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Tavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pizzorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Soldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"1577_CR1","first-page":"390","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho YY, Lagares D, Tager AM, Kapoor M. Fibrosis\u2014a lethal component of systemic sclerosis. Nature. 2014;10:390\u2013402.","journal-title":"Nature"},{"key":"1577_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.39865","volume":"69","author":"JHW Distler","year":"2017","unstructured":"Distler JHW, Feghali-Bostwick C, Soare A, Asano Y, Distler O, Abraham DJ. Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol. 2017;69:257\u201367.","journal-title":"Arthritis Rheumatol"},{"key":"1577_CR3","doi-asserted-by":"publisher","unstructured":"Cutolo M, Ruaro B, Smith V. Macrocirculation versus microcirculation and digital ulcers in systemic sclerosis patients: macro-microcirculation and scleroderma. Rheumatology (Oxford). 2017;23 https:\/\/doi.org\/10.1093\/rheumatology\/kex165 . [Epub ahead of print]","DOI":"10.1093\/rheumatology\/kex165"},{"key":"1577_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.yjmcc.2016.05.002","volume":"97","author":"A Stempien-Otero","year":"2016","unstructured":"Stempien-Otero A, Kim DH, Davis J. Molecular networks underlying myofibroblast fate and fibrosis. J Mol Cell Cardiol. 2016;97:153\u201361.","journal-title":"J Mol Cell Cardiol"},{"key":"1577_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3899\/jrheum.141070","volume":"42","author":"M Cutolo","year":"2015","unstructured":"Cutolo M, Montagna P, Brizzolara R, Smith V, Alessandri E, Villaggio B, et al. Effects of macitentan and its active metabolite on cultured human systemic sclerosis and control skin fibroblasts. J Rheumatol. 2015;42:456\u201363.","journal-title":"J Rheumatol"},{"key":"1577_CR6","doi-asserted-by":"publisher","first-page":"e41994","DOI":"10.1371\/journal.pone.0041994","volume":"7","author":"L Yang","year":"2012","unstructured":"Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, et al. Periostin facilitates skin sclerosis via PI3K\/Akt dependent mechanism in a mouse model of scleroderma. PLoS One. 2012;7:e41994.","journal-title":"PLoS One"},{"key":"1577_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40139-015-0077-z","volume":"3","author":"W He","year":"2015","unstructured":"He W, Dai C. Key fibrogenic signalling. Curr Pathobil Rep. 2015;3:183\u201392.","journal-title":"Curr Pathobil Rep"},{"key":"1577_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","volume":"74","author":"C Beyer","year":"2015","unstructured":"Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling. Ann Rheum Dis. 2015;74:1408\u201316.","journal-title":"Ann Rheum Dis"},{"key":"1577_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13075-015-0754-7","volume":"17","author":"P Cipriani","year":"2015","unstructured":"Cipriani P, Di Benedetto P, Ruscitti P, Verzella D, Fischietti M, Zazzeroni F, et al. Macitentan inhibits the transforming growth factor-\u03b2 profibrotic action, blocking the signaling mediated by the ETR\/T\u03b2RI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2015;17:247. https:\/\/doi.org\/10.1186\/s13075-015-0754-7 .","journal-title":"Arthritis Res Ther"},{"key":"1577_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrneph.2016.54","volume":"12","author":"M Edeling","year":"2016","unstructured":"Edeling M, Ragi G, Huang S, Pavenst\u00e4dt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12:426\u201339.","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl. 92","key":"1577_CR11","first-page":"S3","volume":"33","author":"CP Denton","year":"2015","unstructured":"Denton CP. Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol. 2015;33(Suppl. 92):S3\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1577_CR12","first-page":"484","volume":"35","author":"S Soldano","year":"2017","unstructured":"Soldano S, Paolino S, Pizzorni C, Trombetta AC, Montagna P, Brizzolara R, et al. Dual endothelin receptor antagonists contrast the effects induced by endothelin-1 on cultured human microvascular endothelial cells. Clin Exp Rheumatol. 2017;35:484\u201393.","journal-title":"Clin Exp Rheumatol"},{"key":"1577_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2183\/pjab.83.296","volume":"83","author":"S Narumiya","year":"2007","unstructured":"Narumiya S. Physiology and pathophysiology of prostanoid receptors. Proc Jpn Acad Ser B Phys Biol Sci. 2007;83:296\u2013319.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"1577_CR14","first-page":"625","volume":"24","author":"H Wise","year":"2003","unstructured":"Wise H. Multiple signalling options for prostacyclin. Acta Pharmacol Sin. 2003;24:625\u201330.","journal-title":"Acta Pharmacol Sin"},{"key":"1577_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1124\/jpet.116.239665","volume":"362","author":"J Gatfield","year":"2017","unstructured":"Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, et al. Selexipag active metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low \u03b2-arrestin recruitment and desensitization potential. J Pharmacol Exp Ther. 2017;362:186\u201399.","journal-title":"J Pharmacol Exp Ther"},{"key":"1577_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/01.RES.0000121568.40692.97","volume":"94","author":"R Li","year":"2004","unstructured":"Li R, Cindrova-Davies T, Skepper JN, Sellers LA. Prostacyclin induces apoptosis of vascular smooth cells by cAMP-mediated inhibition of extracellular signal-regulated kinase activity and can counteract the mitogen activity of endothelin-1 or basic growth factor. Circul Res. 2004;94:759\u201367.","journal-title":"Circul Res"},{"key":"1577_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.pan.2014.02.009","volume":"14","author":"Y Niina","year":"2014","unstructured":"Niina Y, Ito T, Oono T, Nakamura T, Fijimori N, Igarashi H, et al. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2014;14:201\u201310.","journal-title":"Pancreatology"},{"key":"1577_CR18","doi-asserted-by":"publisher","first-page":"e98483","DOI":"10.1371\/journal.pone.0098483","volume":"9","author":"Y Chen","year":"2014","unstructured":"Chen Y, Yang S, Yao W, Zhu H, Xu X, Meng G, Zhang W. Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF \u03b2-Smad signal pathway. PLoS One. 2014;9:e98483.","journal-title":"PLoS One"},{"key":"1577_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1183\/09031936.00137511","volume":"40","author":"G Simonneau","year":"2012","unstructured":"Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karl\u00f3cai K, Gali\u00e8 N, Degano B, et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012;40:874\u201380.","journal-title":"Eur Respir J"},{"key":"1577_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cjca.2014.10.024","volume":"31","author":"S Provencher","year":"2015","unstructured":"Provencher S, Granton JT. Current treatment approaches to pulmonary arterial hypertension. Can J Cardiol. 2015;31:460\u201377.","journal-title":"Can J Cardiol"},{"key":"1577_CR21","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"1577_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/ard.2010.142489","volume":"70","author":"C Beyer","year":"2011","unstructured":"Beyer C, Distler JH, Allanore Y, Aringer M, Avouac J, Czirijak L, et al. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis. 2011;70:1178\u201382.","journal-title":"Ann Rheum Dis"},{"key":"1577_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/ard.2008.097378","volume":"68","author":"S Soldano","year":"2009","unstructured":"Soldano S, Montagna P, Villaggio B, Parodi A, Gianotti G, Sulli A, et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis. 2009;68:599\u2013602.","journal-title":"Ann Rheum Dis"},{"key":"1577_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/jpet.112.197152","volume":"343","author":"K Morrison","year":"2012","unstructured":"Morrison K, Studer R, Emst R, Haag F, Kauser K, Clozel M. Different effects of selexipag and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther. 2012;343:547\u201355.","journal-title":"J Pharmacol Exp Ther"},{"key":"1577_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000367630","volume":"94","author":"S Bruderer","year":"2014","unstructured":"Bruderer S, Hurst N, Kaufmann P, Dingemanse J. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94:148\u201356.","journal-title":"Pharmacology"},{"key":"1577_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s13318-017-0424-z","volume":"43","author":"M Boehler","year":"2018","unstructured":"Boehler M, Bruderer S, Ul\u010d I, Dingemanse J. Biocomparison study of adult and paediatric dose strengths of the prostacyclin receptor agonist selexipag. Eur J Drug Metab Pharmacokinet. 2018;43:115\u201320.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1577_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method. Method. 2001;25:402\u20138.","journal-title":"Method"},{"key":"1577_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1124\/jpet.108.138305","volume":"326","author":"K Kuwano","year":"2008","unstructured":"Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5, 6-diphenylpyrazin-2-yl)(isopropyl) amino] butoxy}-N-(methylsulfonyl) acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form,{4-[(5, 6-diphenylpyrazin- 2-yl)(isopropyl) amino] butoxy} acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008;326:691\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"1577_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.bjp.0707413","volume":"152","author":"J Stitham","year":"2007","unstructured":"Stitham J, Arehart E, Gleim SR, Li N, Douville K, Hwa J. New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues. Br J Pharmacol. 2007;152:513\u201322.","journal-title":"Br J Pharmacol"},{"key":"1577_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40264-015-0365-x","volume":"39","author":"C O'Connell","year":"2016","unstructured":"O'Connell C, Amar D, Boucly A, Savale L, Ja\u00efs X, Chaumais MC, et al. Comparative safety and tolerability of prostacyclins in pulmonary hypertension. Drug Saf. 2016;39:287\u201394.","journal-title":"Drug Saf"},{"key":"1577_CR31","doi-asserted-by":"publisher","unstructured":"Morrison K, Haag F, Ernst R, Iglarz M, Clozel M. Selective prostacyclin receptor agonist selexipag, in contrast to prostacyclin analogs, does not evoke paradoxical vasoconstriction of rat femoral artery. J Pharmacol Exp Ther. 2018. https:\/\/doi.org\/10.1124\/jpet.117.246058 . [Epub ahead of print].","DOI":"10.1124\/jpet.117.246058"},{"key":"1577_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00018-015-2110-0","volume":"73","author":"I Darby","year":"2016","unstructured":"Darby I, Zakuan N, Billet F, Desmouli\u00e8re A. The myofibroblasts, a key cell in normal and pathological tissue repair. Cell Mol Life Sci. 2016;73:1145\u201357.","journal-title":"Cell Mol Life Sci"},{"key":"1577_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2014.00123","volume":"5","author":"RT Kendall","year":"2014","unstructured":"Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:123. https:\/\/doi.org\/10.3389\/fphar.2014.00123 .","journal-title":"Front Pharmacol"},{"key":"1577_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1172\/JCI12020","volume":"108","author":"R Stratton","year":"2001","unstructured":"Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest. 2001;108:241\u201350.","journal-title":"J Clin Invest"},{"key":"1577_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1165\/rcmb.2007-0009OC","volume":"37","author":"K Kamio","year":"2007","unstructured":"Kamio K, Liu X, Sugiura H, Togo S, Kobayashi T, Kawasaki S, et al. Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway. Am J Respir Cell Mol Biol. 2007;37:113\u201320.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1577_CR36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/ecn.2015.0360","volume":"26","author":"J Jing","year":"2015","unstructured":"Jing J, Dou TT, Yang JQ, Chen XB, Cao HL, Min M, et al. Role of endothelin-1 in skin fibrosis of systemic sclerosis. Eur Cyt Netw. 2015;26:10\u20134.","journal-title":"Eur Cyt Netw"},{"key":"1577_CR37","doi-asserted-by":"publisher","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","volume":"304","author":"M Zeisberg","year":"2013","unstructured":"Zeisberg M, Kalluri R. Cellular mechanisms of fibrosis. Common and organ-specific mechanisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 2013;304:C216\u201325.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1577_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","volume":"10","author":"R Lafyatis","year":"2014","unstructured":"Lafyatis R. Transforming growth factor \u03b2\u2014at the centre of systemic sclerosis. Nat Rev Rheumatol. 2014;10:706\u201319.","journal-title":"Nat Rev Rheumatol"},{"key":"1577_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.lfs.2013.12.024","volume":"118","author":"F Rodriguez-Pascual","year":"2014","unstructured":"Rodriguez-Pascual F, Busnadiego O, Gonzalez-Santamaria J. The profibrotic role of endothelin-1: is the door still open for the treatment of fibrotic diseases? Life Sci. 2014;118:156\u201364.","journal-title":"Life Sci"},{"key":"1577_CR40","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1476-5381.2012.02190.x","volume":"168","author":"AS Ahmedat","year":"2013","unstructured":"Ahmedat AS, Warnken M, Seemann WK, Mohr K, Kostenis E, Juergens UR, et al. Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine\/paracrine endothelinergic system. Br J Pharmacol. 2013;168:471\u201387.","journal-title":"Br J Pharmacol"},{"key":"1577_CR41","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1165\/rcmb.2011-0446OC","volume":"47","author":"D Lagares","year":"2012","unstructured":"Lagares D, Busnadiego O, Garcia-Fernandez RA, Lamas S, Rodriguez-Pascual F. Adenoviral gene transfer of endothelin-1 in the lung induces pulmonary fibrosis through the activation of focal adhesion kinase. Am J Respir Cell Mol Biol. 2012;47:834\u201342.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1577_CR42","doi-asserted-by":"publisher","unstructured":"Tsoyi K, Chu SG, Patino-Jaramillo NG, Wilder J, Villalba J, Doyle-Eisele M, et al. Syndecan-2 attenuates radiation-induced pulmonary fibrosis and inhibits fibroblast activation by regulating PI3K\/Akt\/ROCK pathway via CD148. Am J Respir Cell Mol Biol. 2017; https:\/\/doi.org\/10.1165\/rcmb.2017-0088OC .","DOI":"10.1165\/rcmb.2017-0088OC"},{"key":"1577_CR43","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3389\/fphar.2017.00428","volume":"8","author":"S Phosri","year":"2017","unstructured":"Phosri S, Arieyawong A, Bunrukchai K, Parichatikanond W, Nishimura A, Nishida M, Mangmool S. Stimulation of adenosine A2B receptor inhibits endothelin-1-induced cardiac fibroblast proliferation and \u03b1-smooth muscle actin synthesis through the cAMP\/Epac\/PI3K\/Akt-signaling pathway. Front Pharmacol. 2017;8:428. https:\/\/doi.org\/10.3389\/fphar.2017.00428 .","journal-title":"Front Pharmacol"},{"key":"1577_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biocel.2011.10.011","volume":"44","author":"JC Horowitz","year":"2012","unstructured":"Horowitz JC, Ajayi IO, Kulasekaran P, Rogers DS, White JB, Townsend SK, et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol. 2012;44:158\u201369.","journal-title":"Int J Biochem Cell Biol"},{"key":"1577_CR45","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1091\/mbc.E03-12-0902","volume":"15","author":"X Shi-Wen","year":"2004","unstructured":"Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac\/phosphoinositide 3-kinase\/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004;15:2707\u201319.","journal-title":"Mol Biol Cell"},{"key":"1577_CR46","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1002\/art.40242","volume":"69","author":"CP Denton","year":"2017","unstructured":"Denton CP, Hachulla \u00c9, Riemekasten G, Schwarting A, Frenoux JM, Frey A, et al. Efficacy and safety of selexipag in adults with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 2017;69:2370\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"1577_CR47","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/rheumatology\/37.9.952","volume":"37","author":"CM Black","year":"1998","unstructured":"Black CM, Halkier-S\u00f8rensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol. 1998;37:952\u201360.","journal-title":"Br J Rheumatol"},{"key":"1577_CR48","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","volume":"41","author":"FM Wigley","year":"1998","unstructured":"Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41:670\u20137.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1577-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1577-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1577-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T12:43:31Z","timestamp":1604234611000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1577-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,2]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1577-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,2]]},"assertion":[{"value":"5 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MC: full professor in Rheumatology, Director of the Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; BR: PhD student in Immunology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; MP: PhD in Internal Medicine and Autoimmunity, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; RB: PhD in Internal Medicine and Autoimmunity, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; ES: trainee in Oncologic Surgery, Department of Surgery, Polyclinic San Martino Hospital; ACT: PhD student in Immunology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; SSca: Hospital doctor and medical executive in Oncologic Surgery, Department of Surgery, Polyclinic San Martino Hospital; PPT: medical surgeon in Dermatology, Unit of Dermatology, University of Genova, Polyclinic San Martino Hospital AP: full professor of Dermatology, Unit of Dermatology, University of Genova, Polyclinic San Martino Hospital; CC: PhD in Rheumatology, Department of Medicine, Surgery and Neurosciences, Scleroderma Unit, University of Siena; NG: associate professor in Medical Science, Surgery and Neurosciences, Department of Medicine, Surgery and Neurosciences, Scleroderma Unit, University of Siena; SP: assistant professor in Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; CP: assistant professor in Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; AS: associate professor in Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital; VS: associate professor in Rheumatology, Department of Rheumatology, Ghent University Hospital; SSol: PhD in Internal Medicine, Autoimmunity and Digestive System Diseases, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The study received approval by the local Ethical Board Committee, protocol ID number: 237REG2015.All patients with SSc and healthy subjects enrolled in the study gave signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"MC obtained funds for research from BMS, Actelion, Celgene, and Boehringer. BR, PM, RB, ES, ACT, SSca, PPT, AP CC, NG, SP, CP, AS, VS, and SSol have no competitive interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"77"}}